Pierfrancesco Tassone
Pierfrancesco Tassone
Professor of Medical Oncology, Magna Graecia University, Catanzaro, Italy
Verified email at
Cited by
Cited by
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The lancet oncology 18 (12), 1688-1700, 2017
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 …
A Chan, S Delaloge, FA Holmes, B Moy, H Iwata, VJ Harvey, NJ Robert, ...
The Lancet Oncology 17 (3), 367-377, 2016
Mir-34: a new weapon against cancer?
G Misso, MT Di Martino, G De Rosa, AA Farooqi, A Lombardi, V Campani, ...
Molecular therapy-nucleic acids 3, 2014
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
M Fulciniti, P Tassone, T Hideshima, S Vallet, P Nanjappa, SA Ettenberg, ...
Blood, The Journal of the American Society of Hematology 114 (2), 371-379, 2009
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells
P Tassone, P Tagliaferri, A Perricelli, S Blotta, B Quaresima, ML Martelli, ...
British journal of cancer 88 (8), 1285-1291, 2003
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells
E Carbone, P Neri, M Mesuraca, MT Fulciniti, T Otsuki, D Pende, V Groh, ...
Blood 105 (1), 251-258, 2005
Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells
L Catley, E Weisberg, T Kiziltepe, YT Tai, T Hideshima, P Neri, P Tassone, ...
Blood 108 (10), 3441-3449, 2006
MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches
N Amodio, L Raimondi, G Juli, MA Stamato, D Caracciolo, P Tagliaferri, ...
Journal of hematology & oncology 11, 1-19, 2018
Dysfunctional T regulatory cells in multiple myeloma
RH Prabhala, P Neri, JE Bae, P Tassone, MA Shammas, CK Allam, ...
Blood 107 (1), 301-304, 2006
Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence
MT Di Martino, E Leone, N Amodio, U Foresta, M Lionetti, MR Pitari, ...
Clinical cancer research 18 (22), 6260-6270, 2012
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy
P Correale, MS Rotundo, MT Del Vecchio, C Remondo, C Migali, ...
Journal of immunotherapy 33 (4), 435-441, 2010
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth
E Leone, E Morelli, MT Di Martino, N Amodio, U Foresta, A Gullą, M Rossi, ...
Clinical Cancer Research 19 (8), 2096-2106, 2013
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity
N Amodio, MA Stamato, G Juli, E Morelli, M Fulciniti, M Manzoni, E Taiana, ...
Leukemia 32 (9), 1948-1957, 2018
Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro
P Tassone, P Tagliaferri, C Viscomi, C Palmieri, M Caraglia, ...
British journal of cancer 88 (12), 1971-1978, 2003
miR‐29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma‐related bone disease
M Rossi, MR Pitari, N Amodio, MT Di Martino, F Conforti, E Leone, C Botta, ...
Journal of cellular physiology 228 (7), 1506-1515, 2013
Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines
P Tassone, S Forciniti, E Galea, G Morrone, MC Turco, V Martinelli, ...
Leukemia 14 (5), 841-844, 2000
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor …
YL Wu, Y Cheng, J Zhou, S Lu, Y Zhang, J Zhao, DW Kim, RA Soo, ...
The Lancet Respiratory Medicine 8 (11), 1132-1143, 2020
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1
N Amodio, MT Di Martino, U Foresta, E Leone, M Lionetti, M Leotta, ...
Cell death & disease 3 (11), e436-e436, 2012
Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells
MF Romano, A Lamberti, P Tassone, F Alfinito, S Costantini, F Chiurazzi, ...
Blood, The Journal of the American Society of Hematology 92 (3), 990-995, 1998
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)
D Chauhan, P Neri, M Velankar, K Podar, T Hideshima, M Fulciniti, ...
Blood 109 (3), 1220-1227, 2007
The system can't perform the operation now. Try again later.
Articles 1–20